Cargando…
Losartan ameliorates TGF-β1–induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies
Highly effective modulator therapies dramatically improve the prognosis for those with cystic fibrosis (CF). The triple combination of elexacaftor, tezacaftor, and ivacaftor (ETI) benefits many, but not all, of those with the most common F508del mutation in the CF transmembrane conductance regulator...
Autores principales: | Kim, Michael D., Bengtson, Charles D., Yoshida, Makoto, Niloy, Asef J., Dennis, John S., Baumlin, Nathalie, Salathe, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151698/ https://www.ncbi.nlm.nih.gov/pubmed/35446787 http://dx.doi.org/10.1172/JCI155241 |
Ejemplares similares
-
The CFTR Amplifier Nesolicaftor Rescues TGF-β1 Inhibition of Modulator-Corrected F508del CFTR Function
por: Bengtson, Charles, et al.
Publicado: (2022) -
Nebulized Menthol Impairs Mucociliary Clearance via TRPM8 and MUC5AC/MUC5B in Primary Airway Epithelial Cells
por: Baumlin, Nathalie, et al.
Publicado: (2023) -
Losartan reduces cigarette smoke-induced airway inflammation and mucus hypersecretion
por: Kim, Michael D., et al.
Publicado: (2021) -
An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19
por: Bengtson, Charles D., et al.
Publicado: (2021) -
Role of Smad3 and p38 Signalling in Cigarette Smoke-induced CFTR and BK dysfunction in Primary Human Bronchial Airway Epithelial Cells
por: Sailland, Juliette, et al.
Publicado: (2017)